Table Of Contents
1 Introduction 18
1.1 Objectives Of The Study 18
1.2 Market Definition 18
1.3 Overview Of Europe Clinical Trial Supplies Market 19
1.4 Currency And Pricing 20
1.5 Limitation 20
1.6 Markets Covered 21
2 Market Segmentation 23
2.1 Markets Covered 23
2.2 Geographic Scope 24
2.3 Years Considered For The Study 25
2.4 Currency And Pricing 25
2.5 Research Methodology 26
2.6 Primary Interviews With Key Opinion Leaders 29
2.7 DBMR Market Challenge Matrix 30
2.8 Secondary Sources 31
2.9 Assumptions 31
3 Market Overview 32
3.1 Drivers 34
3.1.1 Rising Demand Of Clinical Trials Worldwide 34
3.1.2 Increasing Incidences Of Diseases 35
3.1.3 Government Funds To R&D Investments 36
3.1.4 Development Of New Treatments Such As Personalized Medicine 36
3.2 Restraints 37
3.2.1 Adverse Effects Of Clinical Trials 37
3.2.2 Transportation Issue 37
3.3 Opportunities 38
3.3.1 New Drug Development And Availability In Emerging Countrires 38
3.4 Challenges 39
3.4.1 Longer Procedure Time Of Clinical Trials Approval 39
4 Executive Summary 40
5 Premium Insights 42
6 Europe Clinical Trial Supplies Market, By Services 44
6.1 Overview 45
6.2 Storage 47
6.3 Manufacturing 49
6.4 Packaging And Labeling 50
6.5 Distribution 52
7 Europe Clinical Trial Supplies Market, By Clinical Phases 53
7.1 Overview 54
7.2 Phase Iii 56
7.3 Phase Ii 57
7.4 Phase Iv 58
7.5 Phase I 59
8 Mjkeurope Clinical Trial Supplies Market, By Therapeutic Use 61
8.1 Overview 62
8.2 Oncology 64
8.3 Cardiovascular Disease 66
8.4 Dermatology 67
8.5 Metabolic Disorders 68
8.6 Infectious Disease 69
8.7 Respiratory Diseases 70
8.8 Cns And Mental Disorders 71
8.9 Blood Disorders 72
8.10 Others 73
9 Europe Clinical Trial Supplies Market, By End User 74
9.1 Overview 75
9.2 Contract Research Organizations 77
9.3 Pharmaceutical And Biotechnology Companies 78
10 Europe Clinical Trial Supplies Market, By Geography 80
10.1 Europe 80
10.1.1 Germany 87
10.1.2 France 89
10.1.3 U.K. 91
10.1.4 Italy 93
10.1.5 Spain 95
10.1.6 Netherlands 97
10.1.7 Russia 99
10.1.8 Belgium 101
10.1.9 Turkey 103
10.1.10 Switzerland 105
10.1.11 Rest Of Europe 107
11 Europe Clinical Trial Supplies Market, Company Landscape 108
11.1 Company Share Analysis; Europe 108
12 Company Profile 109
12.1 Thermo Fisher Scientific Inc. 109
12.1.1 Company Overview 109
12.1.2 Revenue Analysis 109
12.1.3 Company Share Analysis 110
12.1.4 Product Portfolio 110
12.1.5 Recent Developments 111
12.2 Catalent, Inc.112
12.2.1 Company Overview 112
12.2.2 Revenue Analysis 112
12.2.3 Company Share Analysis 113
12.2.4 Product Portfolio 113
12.2.5 Recent Developments 114
12.3 Clinigen Group Plc. 115
12.3.1 Company Overview 115
12.3.2 Revenue Analysis 115
12.3.3 Revenue Analysis 116
12.3.4 Product Portfolio 116
12.3.5 Recent Developments 116
12.4 Parexel International Corporation 117
12.4.1 Company Overview 117
12.4.2 Revenue Analysis 117
12.4.3 Company Share Analysis 118
12.4.4 Product Portfolio 118
12.4.5 Recent Developments 118
12.5 Alium Medical Limited 119
12.5.1 Company Overview 119
12.5.2 Product Portfolio 119
12.5.3 Recent Developments 119
12.6 Almac Group 120
12.6.1 Company Overview 120
12.6.2 Geographic Presence 120
12.6.3 Product Portfolio 121
12.6.4 Recent Developments 121
12.7 Ancillare, Lp 122
12.7.1 Company Overview 122
12.7.2 Geographic Presence 122
12.7.3 Product Portfolio 123
12.7.4 Recent Developments 123
12.8 Biocair 124
12.8.1 Company Overview 124
12.8.2 Product Portfolio 124
12.8.3 Recent Developments 124
12.9 Bionical Ltd. 125
12.9.1 Company Overview 125
12.9.2 Gepographic Presence 125
12.9.3 Product Portfolio 126
12.9.4 Recent Developments 126
12.10 Clinical Supplies Management Holdings, Inc. 127
12.10.1 Company Overview 127
12.10.2 Geographic Presence 127
12.10.3 Product Portfolio 128
12.10.4 Recent Developments 128
12.11 Klifo 129
12.11.1 Company Overview 129
12.11.2 Geographic Presence 129
12.11.3 Product Portfolio 130
12.11.4 Recent Developments 130
12.12 Movianto 131
12.12.1 Company Overview 131
12.12.2 Geographic Presence 131
12.12.3 Product Portfolio 132
12.12.4 Recent Developments 132
12.13 Myoderm 133
12.13.1 Company Overview 133
12.13.2 Geographic Presence 133
12.13.3 Product Portfolio 134
12.13.4 Recent Developments 134
12.14 Pci Pharma Services 135
12.14.1 Company Overview 135
12.14.2 Geographic Presence 135
12.14.3 Product Portfolio 136
12.14.4 Recent Developments 136
12.15 Sharp 137
12.15.1 Company Overview 137
12.15.2 Geographic Presence 137
12.15.3 Product Portfolio 138
12.15.4 Recent Developments 139
12.16 Siro Clinpharm 140
12.16.1 Company Overview 140
12.16.2 Geographic Presence 140
12.16.3 Product Portfolio 141
12.16.4 Recent Developments 141
13 Related Reports 142